nach oben

Erschienen in:

19.01.2021 | Original Research

Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review

verfasst von: Amy J. Kennedy, MD, MS, Charles B. Wessel, MLS, Rebecca Levine, MD, Kendall Downer, MD, Megan Raymond, BS, Deborah Osakue, MS, Iman Hassan, MD, MS, Jessica S. Merlin, MD, MBA, PhD, Jane M. Liebschutz, MD, MPH

Erschienen in: Journal of General Internal Medicine | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

ABSTRACT

Background

The average length of buprenorphine treatment for opioid use disorder is less than 6 months.

Objective

We conducted a systematic review to determine what factors were associated with longer retention in buprenorphine treatment.

Design

We searched Medline, Embase, and Cochrane Database of Systematic Reviews in February 2018. Articles were restricted to randomized controlled trials on human subjects, written in English, which contained ≥ 24 weeks of objective data on retention in buprenorphine treatment.

Main Measures

We assessed whether dose of buprenorphine, treatment setting, or co-administration of behavioral therapy was associated with retention rates.

Key Results

Over 14,000 articles were identified. Thirteen articles (describing 9 studies) met inclusion criteria. Measures of retention varied widely. Three studies compared doses of buprenorphine between 1 and 8 mg and showed significantly higher rates of retention with higher doses (p values < 0.01). All other studies utilized buprenorphine doses between 8 and 24 mg daily, without comparison. No study found a significant difference in retention between buprenorphine alone and buprenorphine plus behavioral therapy (p values > 0.05). Initiating buprenorphine while hospitalized or within criminal justice settings prior to outpatient treatment programs was significantly associated with retention in buprenorphine treatment (p values < 0.01 respectively).

Conclusions

Setting of treatment initiation and a higher buprenorphine dose are associated with improved long-term treatment retention. More objective data on buprenorphine treatment programs are needed, including a standardized approach to defining retention in buprenorphine treatment programs.

Registration

This review was registered with PROSPERO (#CRD42019120336) in March 2019.

Nur mit Berechtigung zugänglich

National Survey on Drug Use and Health. 2018 NSDUH Annual National Report | CBHSQ. Annual Report.

Ronan M V., Herzig SJ. Hospitalizations related to opioid abuse/dependence and associated serious infections increased sharply, 2002-12. Health Aff. 2016;35(5):832-837. https://doi.org/10.1377/hlthaff.2015.1424CrossRef

Zibbell JE, Asher AK, Patel RC, et al. Increases in Acute Hepatitis C Virus Infection Related to a Growing Opioid Epidemic and Associated Injection Drug Use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175-181. https://doi.org/10.2105/AJPH.2017.304132CrossRefPubMedPubMedCentral

Peters PJ, Pontones P, Hoover KW, et al. HIV infection linked to injection use of oxymorphone in Indiana, 2014-2015. N Engl J Med. 2016;375(3):229-239. https://doi.org/10.1056/NEJMoa1515195CrossRefPubMed

Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. Drug Alcohol Depend. 2009;105(1-2):9-15. https://doi.org/10.1016/j.drugalcdep.2009.05.021CrossRefPubMed

Grönbladh L, Öhlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr Scand. 1990;82(3):223-227. https://doi.org/10.1111/j.1600-0447.1990.tb03057.xCrossRefPubMed

Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-367. https://doi.org/10.1097/ADM.0000000000000166CrossRefPubMedPubMedCentral

Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949-958. https://doi.org/10.1056/NEJMoa022164CrossRefPubMed

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;2014(2). https://doi.org/10.1002/14651858.CD002207.pub4

10.

Pearce LA, Min JE, Piske M, et al. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: Population based retrospective cohort study. BMJ. 2020;368. https://doi.org/10.1136/bmj.m772

11.

Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Ann Intern Med. 2018;169(3):137-145. https://doi.org/10.7326/M17-3107CrossRefPubMedPubMedCentral

12.

Tkacz J, Severt J, Cacciola J, Ruetsch C. Compliance with buprenorphine medication-assisted treatment and relapse to opioid use. Am J Addict. 2012;21(1):55-62. https://doi.org/10.1111/j.1521-0391.2011.00186.xCrossRefPubMed

13.

Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018;85:90-96. https://doi.org/10.1016/j.jsat.2017.07.001CrossRefPubMed

14.

Bentzley BS, Barth KS, Back SE, Book SW. Discontinuation of buprenorphine maintenance therapy: Perspectives and outcomes. J Subst Abuse Treat. 2015;52:48-57. https://doi.org/10.1016/j.jsat.2014.12.011CrossRefPubMed

15.

Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: Prospective observational study in UK General Practice Research Database. BMJ. 2010;341(7779):928. https://doi.org/10.1136/bmj.c5475CrossRef

16.

Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: A systematic review. J Addict Dis. 2016;35(1):22-35. https://doi.org/10.1080/10550887.2016.1100960CrossRefPubMed

17.

Williams AR, Nunes E V., Bisaga A, et al. Developing an opioid use disorder treatment cascade: A review of quality measures. J Subst Abuse Treat. 2018;91:57-68. https://doi.org/10.1016/j.jsat.2018.06.001CrossRefPubMedPubMedCentral

18.

Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(7829). https://doi.org/10.1136/bmj.d5928

19.

Ahmadi J, Bahrami N. Buprenorphine treatment of opium-dependent outpatients seeking treatment in Iran. J Subst Abuse Treat. 2002;23(4):415-417. https://doi.org/10.1016/S0740-5472(02)00272-6CrossRefPubMed

20.

Ahmadi J, Ahmadi M. Twelve-month maintenance treatment of heroin-dependent outpatients with buprenorphine. J Subst Use. 2003;8(1):39-41. https://doi.org/10.1080/1465989031000067236CrossRef

21.

Ahmadi J, Babaee-Beigi M, Alishahi M, Maany I, Hidari T. Twelve-month maintenance treatment of opium-dependent patients. J Subst Abuse Treat. 2004;26(1):61-64. https://doi.org/10.1016/S0740-5472(03)00141-7CrossRef

22.

Fiellin DA, Pantalon M V., Chawarski MC, et al. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365-374. https://doi.org/10.1056/NEJMoa055255CrossRefPubMed

23.

Mitchell SG, Gryczynski J, Schwartz RP, O’Grady KE, Olsen YK, Jaffe JH. A randomized trial of intensive outpatient (IOP) vs. standard outpatient (OP) buprenorphine treatment for African Americans. Drug Alcohol Depend. 2013;128(3):222-229. https://doi.org/10.1016/j.drugalcdep.2012.08.027CrossRefPubMed

24.

Moore BA, Fiellin DA, Cutter CJ, et al. Cognitive Behavioral Therapy Improves Treatment Outcomes for Prescription Opioid Users in Primary Care Buprenorphine Treatment. J Subst Abuse Treat. 2016;71:54-57. https://doi.org/10.1016/j.jsat.2016.08.016CrossRefPubMedPubMedCentral

25.

Gordon MS, Kinlock TW, Schwartz RP, O’Grady KE, Fitzgerald TT, Vocci FJ. A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release. Drug Alcohol Depend. 2017;172:34-42. https://doi.org/10.1016/j.drugalcdep.2016.11.037CrossRefPubMedPubMedCentral

26.

Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: A randomized clinical trial. JAMA Intern Med. 2014;174(8):1369-1376. https://doi.org/10.1001/jamainternmed.2014.2556CrossRefPubMedPubMedCentral

27.

Marsch LA, Bickel WK, Badger GJ, Jacobs EA. Buprenorphine treatment for opioid dependence: The relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend. 2005;77(2):195-204. https://doi.org/10.1016/j.drugalcdep.2004.08.011CrossRefPubMed

28.

Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry. 1996;53(5):401-407. https://doi.org/10.1001/archpsyc.1996.01830050035005CrossRefPubMed

29.

Garcia CA, Correa GC, Viver ADH, et al. Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico. J Addict Med. 2007;1(3):126-132. https://doi.org/10.1097/ADM.0b013e31814b8880CrossRefPubMed

30.

Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial. Drug Alcohol Depend. 2009;99(1-3):222-230. https://doi.org/10.1016/j.drugalcdep.2008.08.006CrossRefPubMed

31.

Zaller N, McKenzie M, Friedmann PD, Green TC, McGowan S, Rich JD. Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abuse Treat. 2013;45(2):222-226. https://doi.org/10.1016/j.jsat.2013.02.005CrossRefPubMedPubMedCentral

32.

Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A Systematic Review on the Use of Psychosocial Interventions in Conjunction with Medications for the Treatment of Opioid Addiction. J Addict Med. 2016;10(2):93-103. https://doi.org/10.1097/ADM.0000000000000193CrossRefPubMed

33.

Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793-800. https://doi.org/10.1093/cid/ciq243CrossRefPubMedPubMedCentral

34.

Williams AR, Nunes E V., Bisaga A, Levin FR, Olfson M. Development of a Cascade of Care for responding to the opioid epidemic. Am J Drug Alcohol Abuse. 2019;45(1):1-10. https://doi.org/10.1080/00952990.2018.1546862CrossRefPubMedPubMedCentral

Titel: Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review
verfasst von: Amy J. Kennedy, MD, MS
Charles B. Wessel, MLS
Rebecca Levine, MD
Kendall Downer, MD
Megan Raymond, BS
Deborah Osakue, MS
Iman Hassan, MD, MS
Jessica S. Merlin, MD, MBA, PhD
Jane M. Liebschutz, MD, MPH
Publikationsdatum: 19.01.2021
Verlag: Springer International Publishing
Erschienen in: Journal of General Internal Medicine / Ausgabe 2/2022
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-020-06448-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Factors Associated with Long-Term Retention in Buprenorphine-Based Addiction Treatment Programs: a Systematic Review